4.6 Article

ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model

期刊

LIFE-BASEL
卷 13, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/life13010100

关键词

non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; liver fibrosis; angiogenesis; lemon balm

向作者/读者索取更多资源

ALS-L1023, extracted from lemon balm, is a natural medicine with anti-angiogenesis properties. This study aimed to investigate the potential of ALS-L1023 in alleviating liver fibrosis in a non-alcoholic fatty liver disease (NAFLD) model. Results showed that ALS-L1023 treatment led to decreased levels of liver enzymes and fibrosis area compared to the control group. RNA sequencing revealed lower expression of genes related to the hedgehog-signaling pathway in the responder group. These findings suggest that ALS-L1023 may be a promising treatment for liver fibrosis in NAFLD.
ALS-L1023 is an ingredient extracted from Melissa officinalis L. (Labiatae; lemon balm), which is known as a natural medicine that suppresses angiogenesis. Herein, we aimed to determine whether ALS-L1023 could alleviate liver fibrosis in the non-alcoholic fatty liver disease (NAFLD) model. C57BL/6 wild-type male mice (age, 6 weeks old) were fed a choline-deficient high-fat diet (CDHFD) for 10 weeks to induce NAFLD. For the next 10 weeks, two groups of mice received the test drug along with CDHFD. Two doses (a low dose, 800 mg/kg/day; and a high dose, 1200 mg/kg/day) of ALS-L1023 were selected and mixed with feed for administration. Obeticholic acid (OCA; 10 mg/kg/day) was used as the positive control. Biochemical analysis revealed that the ALS-L1023 low-dose group had significantly decreased alanine transaminase and aspartate transaminase. The area of fibrosis significantly decreased due to the administration of ALS-L1023, and the anti-fibrotic effect of ALS-L1023 was greater than that of OCA. RNA sequencing revealed that the responder group had lower expression of genes related to the hedgehog-signaling pathway than the non-responder group. ALS-L1023 may exert anti-fibrotic effects in the NAFLD model, suggesting that it may provide potential benefits for the treatment of liver fibrosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据